Literature DB >> 16504962

Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI.

Marcus D Seemann1, G Meisetschlaeger, J Gaa, E J Rummeny.   

Abstract

OBJECTIVE: To assess the diagnostic value of whole-body positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI), and the fusion of PET and CT (PET/CT) and PET and MRI (PET/MRI) in the detection of metastatic disease of gastrointestinal carcinoid tumors.
MATERIALS AND METHODS: This prospective study included six patients with extensive nonresectable metastases of gastrointestinal carcinoid tumors which were consecutively examined from the base of the skull to the proximal thigh using a state-of-the-art PET/CT scanner and a 1.5 Tesla whole-body MRI scanner. PET was performed with a carbohydrated F-18-labeled somatostatin-receptor ligand ([ superset18 F]FP-Gluc-TOCA) using a Pico-3D PET scanner. CT was performed with a venous-dominant contrast-enhanced phase using a 16-slice CT scanner. MRI was performed with a coronal T2-weighted Half-Fourier Acquired Single-Shot Turbo Spin Echo (HASTE) sequence, a coronal T2-weighted Turbo-Short Tau Inversion-Recovery (STIR) sequence, a coronal T1-weighted Turbo Spin Echo (TSE) sequence and a high resolution axial T2-weighted TSE sequence. The data sets from PET and CT were fused automatically. The PET and MRI data sets were fused manually. Lesions were rated as metastases if they were not clearly identified as benign lesions according to standard radiological criteria.
RESULTS: For PET, CT, MRI, PET/CT, and PET/MRI, the lesion-by-lesion based analysis showed an overall detection rate for liver metastases (n = 391) of 49.9% (P<.001), 37.1% (P<.001), 98.2%, 50.9% (P<.001) and 100%, for lymph node metastases (n = 37) of 91.9%, 83.8%, 64.9%, 100% and 97.3% and for osseous metastases (n = 12) of 100%, 8.3% (P<.005), 66.7%, 100% and 100%.
CONCLUSIONS: PET as single modality revealed the most lymph node and osseous metastases. MRI as single modality revealed the most liver metastases. The combination of molecular/metabolic with anatomical/ morphological information improves the diagnostic accuracy for the detection of metastases in comparison to the single modalities. Whole-body PET/MRI is a very promising diagnostic modality for oncological imaging due to the missing radiation exposure and the high soft tissue resolution of MRI in contrast to CT.

Entities:  

Mesh:

Year:  2006        PMID: 16504962

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  19 in total

1.  An Unusual Cause for Sister Mary Joseph's Nodule: A Case Report.

Authors:  Yasser Aljehani
Journal:  Oman Med J       Date:  2014-11

Review 2.  The imaging features of small bowel tumours.

Authors:  Katherine van Ree; Peter Thurley; Rajeev Singh; Nicholas Hurst; Dominic Clark
Journal:  J Gastrointest Cancer       Date:  2012-09

3.  18F-FDG PET/MRI fusion in characterizing pancreatic tumors: comparison to PET/CT.

Authors:  Mitsuaki Tatsumi; Kayako Isohashi; Hiromitsu Onishi; Masatoshi Hori; Tonsok Kim; Ichiro Higuchi; Atsuo Inoue; Eku Shimosegawa; Yutaka Takeda; Jun Hatazawa
Journal:  Int J Clin Oncol       Date:  2011-02-24       Impact factor: 3.402

4.  In vivo evaluation of (64)Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent.

Authors:  Charles Glaus; Raffaella Rossin; Michael J Welch; Gang Bao
Journal:  Bioconjug Chem       Date:  2010-04-21       Impact factor: 4.774

5.  Impact of CT-based diagnostic imaging on management and outcome of nonfunctioning pancreatic tumors.

Authors:  Katja Maschuw; Volker Fendrich; Peter Langer; C Volland; Annette Ramaswamy; Detlef K Bartsch
Journal:  Langenbecks Arch Surg       Date:  2011-02-12       Impact factor: 3.445

Review 6.  Characteristics of common solid liver lesions and recommendations for diagnostic workup.

Authors:  Nimer Assy; Gattas Nasser; Agness Djibre; Zaza Beniashvili; Saad Elias; Jamal Zidan
Journal:  World J Gastroenterol       Date:  2009-07-14       Impact factor: 5.742

7.  The current role of PET-CT in the characterization of hepatobiliary malignancies.

Authors:  Ginseppe Garcea; Seok Ling Ong; Guy J Maddern
Journal:  HPB (Oxford)       Date:  2009-02       Impact factor: 3.647

Review 8.  Multimodal management of neuroendocrine liver metastases.

Authors:  Andrea Frilling; Georgios C Sotiropoulos; Jun Li; Oskar Kornasiewicz; Ursula Plöckinger
Journal:  HPB (Oxford)       Date:  2010-08       Impact factor: 3.647

9.  The impact of 18F-FDG PET/CT in patients with liver metastases.

Authors:  Siew C Chua; Ashley M Groves; Irfan Kayani; Leon Menezes; Svetislav Gacinovic; Yong Du; Jamshed B Bomanji; Peter J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-23       Impact factor: 9.236

10.  PET/MRI: a different spin from under the rim.

Authors:  Rodney J Hicks; Eddie W F Lau
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.